{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:45:13Z","timestamp":1788547513362,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03585-x","type":"journal-article","created":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T08:16:51Z","timestamp":1733559411000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cutibacterium acnes bacteriophage therapy: exploring a new frontier in acne vulgaris treatment"],"prefix":"10.1007","volume":"317","author":[{"given":"Mehrdad","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,7]]},"reference":[{"key":"3585_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s13555-023-01079-8","volume":"14","author":"C Dessinioti","year":"2024","unstructured":"Dessinioti C, Katsambas A (2024) The Microbiome and Acne: perspectives for treatment. Dermatology Therapy 14:31\u201344","journal-title":"Dermatology Therapy"},{"key":"3585_CR2","doi-asserted-by":"publisher","first-page":"eadg4015","DOI":"10.1126\/sciadv.adg4015","volume":"9","author":"M Wielscher","year":"2023","unstructured":"Wielscher M, Pfisterer K, Samardzic D et al (2023) The phageome in normal and inflamed human skin. Sci Adv 9:eadg4015","journal-title":"Sci Adv"},{"key":"3585_CR3","first-page":"101578","volume":"36","author":"M Vasam","year":"2023","unstructured":"Vasam M, Korutla S, Bohara RA (2023) Acne vulgaris: a review of the pathophysiology, treatment, and recent nanotechnology based advances. Biochem Biophys Rep 36:101578","journal-title":"Biochem Biophys Rep"},{"key":"3585_CR4","doi-asserted-by":"crossref","unstructured":"Chilicka K, Dzie\u0144dziora-Urbi\u0144ska I, Szygu\u0142a R, Asanova B (2022) D. Nowicka. Microbiome and Probiotics in Acne Vulgaris-A Narrative Review. Life (Basel); 12","DOI":"10.3390\/life12030422"},{"key":"3585_CR5","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Pellicer P, Navarro-Moratalla L, N\u00fa\u00f1ez-Delegido E, Ruzafa-Costas B, Ag\u00fcera-Santos J (2022) V. Navarro-L\u00f3pez. Acne, Microbiome, and Probiotics: The Gut-Skin Axis. Microorganisms; 10","DOI":"10.3390\/microorganisms10071303"},{"key":"3585_CR6","doi-asserted-by":"publisher","first-page":"1425675","DOI":"10.3389\/fmed.2024.1425675","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Hu X, Dong G, Wang X, Liu T (2024) Acne treatment: research progress and new perspectives. Front Med (Lausanne) 11:1425675","journal-title":"Front Med (Lausanne)"},{"key":"3585_CR7","doi-asserted-by":"crossref","unstructured":"Natarelli N, Gahoonia N, Sivamani RK (2023) Bacteriophages and the Microbiome in Dermatology: the role of the Phageome and a potential therapeutic strategy. Int J Mol Sci; 24","DOI":"10.3390\/ijms24032695"},{"key":"3585_CR8","doi-asserted-by":"crossref","unstructured":"Jo\u0144czyk-Matysiak E, Weber-D\u0105browska B, \u017baczek M et al (2017) Prospects of phage application in the treatment of Acne caused by Propionibacterium acnes. Front Microbiol; 8","DOI":"10.3389\/fmicb.2017.00164"},{"key":"3585_CR9","doi-asserted-by":"crossref","unstructured":"B. Zalewska-Pi\u0105tek Phage Therapy\u2014Challenges, Opportunities and Future Prospects. In: Pharmaceuticals. (2023)","DOI":"10.3390\/ph16121638"},{"key":"3585_CR10","doi-asserted-by":"crossref","unstructured":"Swallow MA, Fan R, Cohen JM (2022) C. G. Bunick. Antibiotic resistance risk with oral tetracycline treatment of Acne Vulgaris. Antibiot (Basel); 11","DOI":"10.3390\/antibiotics11081032"},{"key":"3585_CR11","doi-asserted-by":"crossref","unstructured":"Wang B, Du L, Dong B, Kou E, Wang L, Zhu Y (2024) Current knowledge and perspectives of phage therapy for combating Refractory Wound infections. Int J Mol Sci; 25","DOI":"10.3390\/ijms25105465"},{"key":"3585_CR12","first-page":"429","volume":"95","author":"C Dessinioti","year":"2022","unstructured":"Dessinioti C, Katsambas A (2022) Antibiotics and Antimicrobial Resistance in Acne: epidemiological trends and clinical practice considerations. Yale J Biol Med 95:429\u2013443","journal-title":"Yale J Biol Med"},{"key":"3585_CR13","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.cmi.2023.01.011","volume":"29","author":"WJ Metsemakers","year":"2023","unstructured":"Metsemakers WJ, Onsea J, Moriarty TF et al (2023) Bacteriophage therapy for human musculoskeletal and skin\/soft tissue infections. Clin Microbiol Infect 29:695\u2013701","journal-title":"Clin Microbiol Infect"},{"key":"3585_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41579-023-00877-3","volume":"21","author":"WPJ Smith","year":"2023","unstructured":"Smith WPJ, Wucher BR, Nadell CD (2023) Foster. Bacterial defences: mechanisms, evolution and antimicrobial resistance. Nat Rev Microbiol 21:519\u2013534","journal-title":"Nat Rev Microbiol"},{"key":"3585_CR15","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-virology-012423-110530","volume":"10","author":"A Orom\u00ed-Bosch","year":"2023","unstructured":"Orom\u00ed-Bosch A, Antani JD (2023) Turner. Developing phage therapy that overcomes the evolution of bacterial resistance. Annu Rev Virol 10:503\u2013524","journal-title":"Annu Rev Virol"},{"key":"3585_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13555-018-0275-9","volume":"9","author":"DE Castillo","year":"2019","unstructured":"Castillo DE, Nanda S (2019) Keri. Propionibacterium (Cutibacterium) acnes bacteriophage therapy in Acne: current evidence and future perspectives. Dermatol Ther (Heidelb) 9:19\u201331","journal-title":"Dermatol Ther (Heidelb)"},{"key":"3585_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.chom.2022.01.007","volume":"30","author":"L Flowers","year":"2022","unstructured":"Flowers L, Campbell A, Uberoi A (2022) Cutibacterium acnes evolution: one pore at a time. Cell Host Microbe 30:144\u2013146","journal-title":"Cell Host Microbe"},{"key":"3585_CR18","doi-asserted-by":"crossref","unstructured":"Kim S, Song H, Jin JS, Lee WJ (2022) J. Kim. Genomic and phenotypic characterization of Cutibacterium acnes bacteriophages isolated from Acne patients. Antibiot (Basel); 11","DOI":"10.3390\/antibiotics11081041"},{"key":"3585_CR19","doi-asserted-by":"crossref","unstructured":"Platsidaki E, Dessinioti C (2018) Recent advances in understanding Propionibacterium acnes (Cutibacterium acnes) in acne. F1000Res; 7","DOI":"10.12688\/f1000research.15659.1"},{"key":"3585_CR20","doi-asserted-by":"publisher","first-page":"e1010420","DOI":"10.1371\/journal.ppat.1010420","volume":"18","author":"N Kn\u00f6dlseder","year":"2022","unstructured":"Kn\u00f6dlseder N, Nevot G, F\u00e1brega MJ et al (2022) Engineering selectivity of Cutibacterium acnes phages by epigenetic imprinting. PLoS Pathog 18:e1010420","journal-title":"PLoS Pathog"},{"key":"3585_CR21","doi-asserted-by":"crossref","unstructured":"Abedon ST (2014) Phage therapy: eco-physiological pharmacology. Scientifica (Cairo); 2014: 581639","DOI":"10.1155\/2014\/581639"},{"key":"3585_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12223-023-01046-y","volume":"68","author":"M Mohammadi","year":"2023","unstructured":"Mohammadi M, Saffari M, Siadat SD (2023) Phage therapy of antibiotic-resistant strains of Klebsiella pneumoniae, opportunities and challenges from the past to the future. Folia Microbiol (Praha) 68:357\u2013368","journal-title":"Folia Microbiol (Praha)"},{"key":"3585_CR23","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2666-5247(24)00002-8","volume":"5","author":"Q Fang","year":"2024","unstructured":"Fang Q, Yin X, He Y et al (2024) Safety and efficacy of phage application in bacterial decolonisation: a systematic review. Lancet Microbe 5:e489\u2013e499","journal-title":"Lancet Microbe"},{"key":"3585_CR24","doi-asserted-by":"crossref","unstructured":"Dicks LMT (2024) W. Vermeulen. Bacteriophage-host interactions and the therapeutic potential of bacteriophages. Viruses; 16","DOI":"10.3390\/v16030478"},{"key":"3585_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s43088-021-00141-8","volume":"10","author":"A Loganathan","year":"2021","unstructured":"Loganathan A, Manohar P, Eniyan K, VinodKumar CS, Leptihn S (2021) Nachimuthu. Phage therapy as a revolutionary medicine against Gram-positive bacterial infections. Beni Suef Univ J Basic Appl Sci 10:49","journal-title":"Beni Suef Univ J Basic Appl Sci"},{"key":"3585_CR26","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s11274-014-1655-7","volume":"30","author":"SA Jassim","year":"2014","unstructured":"Jassim SA, Limoges RG (2014) Natural solution to antibiotic resistance: bacteriophages \u2018The living drugs\u2019. World J Microbiol Biotechnol 30:2153\u20132170","journal-title":"World J Microbiol Biotechnol"},{"key":"3585_CR27","doi-asserted-by":"publisher","first-page":"dlae017","DOI":"10.1093\/jacamr\/dlae017","volume":"6","author":"I Bleriot","year":"2024","unstructured":"Bleriot I, Pacios O, Blasco L et al (2024) Improving phage therapy by evasion of phage resistance mechanisms. JAC Antimicrob Resist 6:dlae017","journal-title":"JAC Antimicrob Resist"},{"key":"3585_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2022.11.017","volume":"186","author":"SA Strathdee","year":"2023","unstructured":"Strathdee SA, Hatfull GF, Mutalik VK (2023) Schooley. Phage therapy: from biological mechanisms to future directions. Cell 186:17\u201331","journal-title":"Cell"},{"key":"3585_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12223-021-00946-1","volume":"67","author":"A Zyman","year":"2022","unstructured":"Zyman A, G\u00f3rski A, Mi\u0119dzybrodzki R (2022) Phage therapy of wound-associated infections. Folia Microbiol (Praha) 67:193\u2013201","journal-title":"Folia Microbiol (Praha)"},{"key":"3585_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1093\/phe\/phaa003","volume":"13","author":"J Anomaly","year":"2020","unstructured":"Anomaly J (2020) The future of phage: ethical challenges of using phage therapy to treat bacterial infections. Public Health Ethics 13:82\u201388","journal-title":"Public Health Ethics"},{"key":"3585_CR31","doi-asserted-by":"crossref","unstructured":"Hasan M (2022) J. Ahn Evolutionary Dynamics between Phages and Bacteria as a Possible Approach for Designing Effective Phage Therapies against Antibiotic-Resistant Bacteria. In: Antibiotics","DOI":"10.3390\/antibiotics11070915"},{"key":"3585_CR32","doi-asserted-by":"crossref","unstructured":"Xu HM, Xu WM, Zhang L (2022) Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases. Int J Clin Pract; 2022: 4913146","DOI":"10.1155\/2022\/4913146"},{"key":"3585_CR33","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","volume":"9","author":"JP Pirnay","year":"2024","unstructured":"Pirnay JP, Djebara S, Steurs G et al (2024) Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol 9:1434\u20131453","journal-title":"Nat Microbiol"},{"key":"3585_CR34","doi-asserted-by":"publisher","first-page":"907314","DOI":"10.3389\/fcimb.2022.907314","volume":"12","author":"L Plumet","year":"2022","unstructured":"Plumet L, Ahmad-Mansour N, Dunyach-Remy C et al (2022) Bacteriophage therapy for Staphylococcus Aureus infections: a review of animal models, treatments, and clinical trials. Front Cell Infect Microbiol 12:907314","journal-title":"Front Cell Infect Microbiol"},{"key":"3585_CR35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2217\/fvl-2022-0229","volume":"18","author":"M Mohammadi","year":"2023","unstructured":"Mohammadi M, Mirabadi M, Beig M, Nasereslami S, Yazdanmehr M (2023) Monfared. The role of Nanotechnology in overcoming barriers to phage therapy: an overview. Future Virol 18:387\u2013398","journal-title":"Future Virol"},{"key":"3585_CR36","doi-asserted-by":"crossref","unstructured":"Lam HYP, Lai MJ, Chen TY, Wu WJ, Peng SY (2021) K. C. Chang. Therapeutic effect of a newly isolated lytic bacteriophage against Multi-drug-resistant Cutibacterium acnes infection in mice. Int J Mol Sci; 22","DOI":"10.3390\/ijms22137031"},{"key":"3585_CR37","doi-asserted-by":"publisher","first-page":"e0151184","DOI":"10.1371\/journal.pone.0151184","volume":"11","author":"TL Brown","year":"2016","unstructured":"Brown TL, Petrovski S, Dyson ZA, Seviour R, Tucci J (2016) The Formulation of Bacteriophage in a Semi Solid Preparation for Control of Propionibacterium acnes growth. PLoS ONE 11:e0151184","journal-title":"PLoS ONE"},{"key":"3585_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5021\/ad.2019.31.1.22","volume":"31","author":"MJ Kim","year":"2019","unstructured":"Kim MJ, Eun DH, Kim SM, Kim J (2019) Lee. Efficacy of bacteriophages in Propionibacterium acnes-Induced inflammation in mice. Ann Dermatol 31:22\u201328","journal-title":"Ann Dermatol"},{"key":"3585_CR39","doi-asserted-by":"crossref","unstructured":"Han MH, Khan SA (2023) G. S. Moon. Cutibacterium acnes KCTC 3314 growth reduction with the combined use of bacteriophage PAP 1\u20131 and Nisin. Antibiot (Basel); 12","DOI":"10.3390\/antibiotics12061035"},{"key":"3585_CR40","doi-asserted-by":"crossref","unstructured":"Liao D, Zhang J, Liu R et al (2023) Whole-genome sequencing, annotation, and biological characterization of a novel Siphoviridae phage against multi-drug resistant Propionibacterium acne. Front Microbiol; 13","DOI":"10.3389\/fmicb.2022.1065386"},{"key":"3585_CR41","doi-asserted-by":"publisher","first-page":"16430","DOI":"10.1038\/s41598-023-43559-z","volume":"13","author":"J-I Kim","year":"2023","unstructured":"Kim J-I, Hasnain MA, Moon G-S (2023) Expression of a recombinant endolysin from bacteriophage CAP 10\u2013\u20093 with lytic activity against Cutibacterium acnes. Sci Rep 13:16430","journal-title":"Sci Rep"},{"key":"3585_CR42","doi-asserted-by":"publisher","first-page":"106111","DOI":"10.1016\/j.micpath.2023.106111","volume":"180","author":"G Xuan","year":"2023","unstructured":"Xuan G, Wang Y, Wang Y, Lin H, Wang C, Wang J (2023) Characterization of the newly isolated phage Y3Z against multi-drug resistant Cutibacterium acnes. Microb Pathog 180:106111","journal-title":"Microb Pathog"},{"key":"3585_CR43","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41467-023-36694-8","volume":"14","author":"A Rimon","year":"2023","unstructured":"Rimon A, Rakov C, Lerer V et al (2023) Topical phage therapy in a mouse model of Cutibacterium acnes-induced acne-like lesions. Nat Commun 14:1005","journal-title":"Nat Commun"},{"key":"3585_CR44","first-page":"e02838","volume":"12","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhen N, Liao D et al (2024) Application of bacteriophage \u03c6PaP11-13 attenuates rat Cutibacterium acnes infection lesions by promoting keratinocytes apoptosis via inhibiting PI3K\/Akt pathway. Microbiol Spectr 12:e02838\u2013e02823","journal-title":"Microbiol Spectr"},{"key":"3585_CR45","first-page":"26","volume":"4","author":"DT Di Bello","year":"2023","unstructured":"Di Bello DT, Narv\u00e1ez DM, Groot de Restrepo H (2023) Vives. Cytotoxic evaluation in HaCaT cells of the Pa.7 bacteriophage from Cutibacterium (Propionibacterium) acnes, Free and Encapsulated within liposomes. Phage (New Rochelle) 4:26\u201334","journal-title":"Phage (New Rochelle)"},{"key":"3585_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12941-023-00567-1","volume":"22","author":"M Mohammadi","year":"2023","unstructured":"Mohammadi M, Saffari M, Siadat SD et al (2023) Isolation, characterization, therapeutic potency, and genomic analysis of a novel bacteriophage vB_KshKPC-M against carbapenemase-producing Klebsiella pneumoniae strains (CRKP) isolated from Ventilator-associated pneumoniae (VAP) infection of COVID-19 patients. Ann Clin Microbiol Antimicrob 22:18","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03585-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03585-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T21:02:09Z","timestamp":1733605329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03585-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3585"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03585-x","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,7]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"84"}}